Advertisement

Topics

Boehringer Ingelheim’s adalimumab biosimilar ‘equivalent’ to Humira

03:58 EDT 23 Jun 2017 | Generics and Biosimilars Initiative

Germany-based biologicals specialist Boehringer Ingelheim (Boehringer) announced on 14 June 2017 positive results from its pivotal phase III study of its candidate adalimumab biosimilar.

Original Article: Boehringer Ingelheim’s adalimumab biosimilar ‘equivalent’ to Humira

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim’s adalimumab biosimilar ‘equivalent’ to Humira"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...